

INVESTORS UPDATE

BSE: 506690	NSE: UNICHEMLAB	Reuters: UNLB.BO	Bloomberg: UN:IN
-------------	-----------------	------------------	------------------

Mumbai, Friday, October 25, 2013

Investors Update on Sale of Indore SEZ Plant

Unichem laboratories Limited had sought approval of shareholders by postal ballot as per the details furnished in the Postal Ballot Notice dated February 15, 2013 sent to all shareholders for the approval of sale of Company's new formulation manufacturing unit located at Indore SEZ on a slump sale basis to M/s Mylan Laboratories Limited.

Result of Postal Ballot pursuant to Section 192A of the Companies Act, 1956 read with Companies (Passing of Resolution by Postal Ballot) Rules, 2001, was announced on March 29, 2013. Total 881 numbers of Postal Ballot Forms / E-Voting confirmations were received: Votes casts in favour of the resolution were over **99.91 %** of the total votes polled and, consequently the Ordinary Resolution mentioned in the Notice was passed by the requisite majority on March 29, 2013.

We are pleased to announce that the consideration amount of Rs.160.50 Crores [Rupees one hundred sixty crores and fifty lacs only] was deposited into an Escrow Account until such time that approvals from various authorities as are required are received to the satisfaction of Buyer and Seller. Since all necessary approvals for completion of the transaction are received, the Company has consequently received the consideration amount of Rs. 160.50 Crores and the sale transaction is completed.



INVESTORS UPDATE

About Unichem Laboratories Limited

Unichem Laboratories Limited is an International, integrated, speciality pharmaceutical Company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the Company is a leader in niche areas of cardiology, neurology and other orthopedics and anti-infectives. The Company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

More information about the Company can be found at www.unichemlabs.com

Contacts:

Mr. M Gundu Rao / Mr. K Subharaman

Ph: +91-22-66888 380

Ph: +91-22-66888 404

E-mail: gundurao@unichemlabs.com

subharamank@unichemlabs.com

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Tel: +91-22-66888 509

E-mail: rparikh@unichemlabs.com

monish.shah@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-o0o-